1 TEAE rates were 73.6% with placebo and 78.9% with LDX; s
2 All 29 participants experienced >=
1 TEAE.
3 5% of patients (654/756) reported at least
1 TEAE during the treatment period; most were mild, nonocu
4 At least
1 TEAE was reported in 97 of 121 patients (80.2%) overall;
5 wAIHA, respectively, experienced at least
1 TEAE.
6 patients; one of whom had a serious grade
3 TEAE of febrile neutropenia that was considered to be re
7 Eleven (38%) experienced >=1 grade
3 TEAE.
8 grade >=3, 2.3%); the most common grade >=
3 TEAE was fatigue (10.2%).
9 Es) were grade 1 or 2; the only grade 3 or
4 TEAE that occurred in more than 5% of patients receiving
10 Twelve (63.2%) participants had
a TEAE, most of which were mild and resolved on the day of
11 Five (8%) patients with
a TEAE had a fatal outcome; none was reported as related t
12 outcome measures were treatment-emergent
AE (
TEAE), AESI, SAE, and ADR occurrences.
13 Dose interruption, dose reduction,
and TEAE-related treatment discontinuation occurred in 66 (5
14 Dysgeusia was the most
common TEAE (78/120; 65%) and led to maribavir discontinuation
15 The most
common TEAE was conjunctival hyperemia (incidence 35.5%, 11/31)
16 The most
common TEAE was headache, reported in 10 participants (8.8%, Pi
17 The most
common TEAE was injection-site bruising (n=14 [16%] in the zilu
18 Diarrhea was the most
common TEAE; most participants with diarrhea also received nint
19 GBR 830 was well tolerated, with
equal TEAE distribution (GBR 830, 63.0% [29/46]; placebo, 63.0
20 d a severe treatment emergent adverse
event (
TEAE) (MDMA-AT, n = 5 (9.4%); placebo with therapy, n =
21 Treatment-emergent adverse
event (
TEAE) and serious TEAE rates compared similarly between
22 Treatment-emergent adverse
event (
TEAE) rates were similar between arms.
23 ost common treatment-emergent adverse
event (
TEAE) was hyperphosphatemia (75.0%; grade >=3, 2.3%); th
24 ost common treatment-emergent adverse
event (
TEAE) was injection site pruritus.
25 ne grade 3 treatment-emergent adverse
event (
TEAE) was reported in 53.4% of patients.
26 s with any treatment-emergent adverse
event (
TEAE) was similar between treatment groups (976 [85.6%]
27 ienced >=1 treatment-emergent adverse
event (
TEAE), and 1 reported >=1 related TEAE (injection site p
28 least one treatment-emergent adverse
event (
TEAE), with the majority grade 1-2 (64 (81%)), five (6%)
29 reported treatment-emergent adverse
events (
TEAE), abnormal laboratory measurements, and incidence o
30 atients with at least one grade 3 or
greater TEAE, the most common TEAEs were neutropenia (24.8%), di
31 studies, grass SLIT-tablet did not
increase TEAE frequency, severe local allergic swelling, or syste
32 (TEAEs), of whom 26.8% experienced an
ocular TEAE in the study eye.
33 The most common
ocular TEAE in both implant- and SLT-treated eyes was increased
34 The most common serious
ocular TEAE was endophthalmitis (0.5% [n = 3]).
35 e all participants experiencing at least
one TEAE, most of these events were mild in nature, exhibite
36 rse event (TEAE), and 1 reported >=1
related TEAE (injection site pain).
37 (HAE-FXII) experienced a garadacimab-
related TEAE (mild injection-site reaction), and patient 3 (HAE-
38 Treatment-
related TEAE frequency ranged from 18% (17/93) for 10 mg once da
39 Serious TEAE incidence rates were higher with evobrutinib than t
40 six (9%) in the placebo group had a
serious TEAE.
41 nt-emergent adverse event (TEAE) and
serious TEAE rates compared similarly between treatment strategi
42 .6% with placebo and 78.9% with LDX;
serious TEAE rates were 4.2 and 2.8%.
43 No
serious TEAE was related to the study drug.
44 One
serious TEAE in the GBR 830 group was deemed unrelated to study
45 ltinib group had a treatment-related
serious TEAE of subcutaneous abscess.
46 (HAE-FXII) experienced an unrelated
serious TEAE (severe HAE attack).
47 olerated; only 1 patient discontinued due
to TEAE.